Some Healthcare Workers Produced a Low Response to COVID-19 Vaccinations in a Study by Cedars-Sinai
Investigators Suspect Prematurely Aging Immune Cells May Prevent a Strong Vaccine Response
A subset of healthcare workers vaccinated against COVID-19 had unexpectedly low responses to the immunizations, according to Cedars-Sinai investigators. The findings of the new study are published in iScience, a Cell Press journal.
In a matched control study, investigators compared the vaccine responses among a group of Cedars-Sinai healthcare workers who were generally in good health. The study participants received the BNT162b2 vaccine produced by Pfizer Inc., and their average age was 48.
“It turns out that a small percentage of the healthcare worker population we studied did not have a robust response to the BNT162b2 vaccine. After vaccination, they produced lower levels of antibodies to the spike protein found on the surface of SARS-CoV-2, the virus that causes COVID-19. That low response persisted even after they received second and third booster doses,” said Peter Chen, MD, who holds the Medallion Chair in Molecular Medicine at Cedars-Sinai and is one of the study’s senior authors.
Investigators noted that the “low responders” in the study were relatively young, but their immune systems reacted to the vaccine as if they were much older.
“The low responders had lymphocytes, white blood cells that are part of the immune system, with characteristics more typically observed in older people or individuals with chronic diseases. We know older people also tend to mount weaker responses to vaccines, so our data suggests this subset of healthcare workers could have immune cells that had prematurely aged and were therefore less responsive to vaccination,” said Helen Goodridge, PhD, a co-senior author of the study, a professor of Biomedical Sciences and a research scientist in the Cedars-Sinai Board of Governors Regenerative Medicine Institute.
This study is part of the ongoing Coronavirus Risk Associations and Longitudinal Evaluation (CORALE) project led by Cedars-Sinai. Investigators say this study finding of a low vaccine response among otherwise healthy people requires further research.
“We would like to study the pathways that led to the premature aging phenotype to determine if it is specifically responsible for lower antibody levels after vaccination and then try and develop a therapeutic intervention to reverse this effect,” said Susan Cheng, MD, MPH, the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science and a corresponding author of the study.
“Also, our study did not evaluate the lymphocytes that are responsible for killing the cells that are already infected with the SARS-CoV-2 virus; this is an important element of immunity against COVID-19,” said Cheng, who is also director of the Institute for Research on Healthy Aging in the Department of Cardiology at the Smidt Heart Institute.
Investigators emphasize that while some people’s immune systems have a low antibody response to the vaccine, the evidence that vaccination is a very effective tool for preventing serious illness and death from COVID-19 remains strong.
“We should all get vaccinated because the BNT162b2 vaccine we studied still provided some immunity in most of the low responders. This group still had memory cells that can generate more antibodies when attacked by the virus, even if at a lower level,” said Chen, director of Pulmonary and Critical Care Medicine at Cedars-Sinai.
Funding: The study was supported by National Institutes of Health grants R01HL155759, R01HL37076, R01HL59953, K08HL141590 and U54CA260591; the Board of Governors Regenerative Medicine Institute, Cedars-Sinai; the Erika J. Glazer Family Foundation; the Plum Foundation; and the Parker B. Francis Foundation.
Read more from the Cedars-Sinai Blog: COVID-19 Vaccine Efficacy: Clearing Up Confusion